Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not pri...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Haijiao Zhang [verfasserIn] Samantha Savage [verfasserIn] Anna Reister Schultz [verfasserIn] Daniel Bottomly [verfasserIn] Libbey White [verfasserIn] Erik Segerdell [verfasserIn] Beth Wilmot [verfasserIn] Shannon K. McWeeney [verfasserIn] Christopher A. Eide [verfasserIn] Tamilla Nechiporuk [verfasserIn] Amy Carlos [verfasserIn] Rachel Henson [verfasserIn] Chenwei Lin [verfasserIn] Robert Searles [verfasserIn] Hoang Ho [verfasserIn] Yee Ling Lam [verfasserIn] Richard Sweat [verfasserIn] Courtney Follit [verfasserIn] Vinay Jain [verfasserIn] Evan Lind [verfasserIn] Gautam Borthakur [verfasserIn] Guillermo Garcia-Manero [verfasserIn] Farhad Ravandi [verfasserIn] Hagop M. Kantarjian [verfasserIn] Jorge Cortes [verfasserIn] Robert Collins [verfasserIn] Daelynn R. Buelow [verfasserIn] Sharyn D. Baker [verfasserIn] Brian J. Druker [verfasserIn] Jeffrey W. Tyner [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2019

Übergeordnetes Werk:	In: Nature Communications - Nature Portfolio, 2016, 10(2019), 1, Seite 13
Übergeordnetes Werk:	volume:10 ; year:2019 ; number:1 ; pages:13

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1038/s41467-018-08263-x

Katalog-ID:	DOAJ061547557

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ061547557
003	DE-627
005	20230309012537.0
007	cr uuu---uuuuu
008	230228s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1038/s41467-018-08263-x \|2 doi
035			\|a (DE-627)DOAJ061547557
035			\|a (DE-599)DOAJ998f439604e74cef95464ecda676fa5a
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Haijiao Zhang \|e verfasserin \|4 aut
245	1	0	\|a Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations.
653		0	\|a Science
653		0	\|a Q
700	0		\|a Samantha Savage \|e verfasserin \|4 aut
700	0		\|a Anna Reister Schultz \|e verfasserin \|4 aut
700	0		\|a Daniel Bottomly \|e verfasserin \|4 aut
700	0		\|a Libbey White \|e verfasserin \|4 aut
700	0		\|a Erik Segerdell \|e verfasserin \|4 aut
700	0		\|a Beth Wilmot \|e verfasserin \|4 aut
700	0		\|a Shannon K. McWeeney \|e verfasserin \|4 aut
700	0		\|a Christopher A. Eide \|e verfasserin \|4 aut
700	0		\|a Tamilla Nechiporuk \|e verfasserin \|4 aut
700	0		\|a Amy Carlos \|e verfasserin \|4 aut
700	0		\|a Rachel Henson \|e verfasserin \|4 aut
700	0		\|a Chenwei Lin \|e verfasserin \|4 aut
700	0		\|a Robert Searles \|e verfasserin \|4 aut
700	0		\|a Hoang Ho \|e verfasserin \|4 aut
700	0		\|a Yee Ling Lam \|e verfasserin \|4 aut
700	0		\|a Richard Sweat \|e verfasserin \|4 aut
700	0		\|a Courtney Follit \|e verfasserin \|4 aut
700	0		\|a Vinay Jain \|e verfasserin \|4 aut
700	0		\|a Evan Lind \|e verfasserin \|4 aut
700	0		\|a Gautam Borthakur \|e verfasserin \|4 aut
700	0		\|a Guillermo Garcia-Manero \|e verfasserin \|4 aut
700	0		\|a Farhad Ravandi \|e verfasserin \|4 aut
700	0		\|a Hagop M. Kantarjian \|e verfasserin \|4 aut
700	0		\|a Jorge Cortes \|e verfasserin \|4 aut
700	0		\|a Robert Collins \|e verfasserin \|4 aut
700	0		\|a Daelynn R. Buelow \|e verfasserin \|4 aut
700	0		\|a Sharyn D. Baker \|e verfasserin \|4 aut
700	0		\|a Brian J. Druker \|e verfasserin \|4 aut
700	0		\|a Jeffrey W. Tyner \|e verfasserin \|4 aut
773	0	8	\|i In \|t Nature Communications \|d Nature Portfolio, 2016 \|g 10(2019), 1, Seite 13 \|w (DE-627)626457688 \|w (DE-600)2553671-0 \|x 20411723 \|7 nnns
773	1	8	\|g volume:10 \|g year:2019 \|g number:1 \|g pages:13
856	4	0	\|u https://doi.org/10.1038/s41467-018-08263-x \|z kostenfrei
856	4	0	\|u https://doaj.org/article/998f439604e74cef95464ecda676fa5a \|z kostenfrei
856	4	0	\|u https://doi.org/10.1038/s41467-018-08263-x \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2041-1723 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_211
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 10 \|j 2019 \|e 1 \|h 13

Indexfelder

author_variant	h z hz s s ss a r s ars d b db l w lw e s es b w bw s k m skm c a e cae t n tn a c ac r h rh c l cl r s rs h h hh y l l yll r s rs c f cf v j vj e l el g b gb g g m ggm f r fr h m k hmk j c jc r c rc d r b drb s d b sdb b j d bjd j w t jwt
matchkey_str	article:20411723:2019----::lncleitneornlnbnctmeodekmautdv
hierarchy_sort_str	2019
publishDate	2019
allfields	10.1038/s41467-018-08263-x doi (DE-627)DOAJ061547557 (DE-599)DOAJ998f439604e74cef95464ecda676fa5a DE-627 ger DE-627 rakwb eng Haijiao Zhang verfasserin aut Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations. Science Q Samantha Savage verfasserin aut Anna Reister Schultz verfasserin aut Daniel Bottomly verfasserin aut Libbey White verfasserin aut Erik Segerdell verfasserin aut Beth Wilmot verfasserin aut Shannon K. McWeeney verfasserin aut Christopher A. Eide verfasserin aut Tamilla Nechiporuk verfasserin aut Amy Carlos verfasserin aut Rachel Henson verfasserin aut Chenwei Lin verfasserin aut Robert Searles verfasserin aut Hoang Ho verfasserin aut Yee Ling Lam verfasserin aut Richard Sweat verfasserin aut Courtney Follit verfasserin aut Vinay Jain verfasserin aut Evan Lind verfasserin aut Gautam Borthakur verfasserin aut Guillermo Garcia-Manero verfasserin aut Farhad Ravandi verfasserin aut Hagop M. Kantarjian verfasserin aut Jorge Cortes verfasserin aut Robert Collins verfasserin aut Daelynn R. Buelow verfasserin aut Sharyn D. Baker verfasserin aut Brian J. Druker verfasserin aut Jeffrey W. Tyner verfasserin aut In Nature Communications Nature Portfolio, 2016 10(2019), 1, Seite 13 (DE-627)626457688 (DE-600)2553671-0 20411723 nnns volume:10 year:2019 number:1 pages:13 https://doi.org/10.1038/s41467-018-08263-x kostenfrei https://doaj.org/article/998f439604e74cef95464ecda676fa5a kostenfrei https://doi.org/10.1038/s41467-018-08263-x kostenfrei https://doaj.org/toc/2041-1723 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2019 1 13
spelling	10.1038/s41467-018-08263-x doi (DE-627)DOAJ061547557 (DE-599)DOAJ998f439604e74cef95464ecda676fa5a DE-627 ger DE-627 rakwb eng Haijiao Zhang verfasserin aut Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations. Science Q Samantha Savage verfasserin aut Anna Reister Schultz verfasserin aut Daniel Bottomly verfasserin aut Libbey White verfasserin aut Erik Segerdell verfasserin aut Beth Wilmot verfasserin aut Shannon K. McWeeney verfasserin aut Christopher A. Eide verfasserin aut Tamilla Nechiporuk verfasserin aut Amy Carlos verfasserin aut Rachel Henson verfasserin aut Chenwei Lin verfasserin aut Robert Searles verfasserin aut Hoang Ho verfasserin aut Yee Ling Lam verfasserin aut Richard Sweat verfasserin aut Courtney Follit verfasserin aut Vinay Jain verfasserin aut Evan Lind verfasserin aut Gautam Borthakur verfasserin aut Guillermo Garcia-Manero verfasserin aut Farhad Ravandi verfasserin aut Hagop M. Kantarjian verfasserin aut Jorge Cortes verfasserin aut Robert Collins verfasserin aut Daelynn R. Buelow verfasserin aut Sharyn D. Baker verfasserin aut Brian J. Druker verfasserin aut Jeffrey W. Tyner verfasserin aut In Nature Communications Nature Portfolio, 2016 10(2019), 1, Seite 13 (DE-627)626457688 (DE-600)2553671-0 20411723 nnns volume:10 year:2019 number:1 pages:13 https://doi.org/10.1038/s41467-018-08263-x kostenfrei https://doaj.org/article/998f439604e74cef95464ecda676fa5a kostenfrei https://doi.org/10.1038/s41467-018-08263-x kostenfrei https://doaj.org/toc/2041-1723 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2019 1 13
allfields_unstemmed	10.1038/s41467-018-08263-x doi (DE-627)DOAJ061547557 (DE-599)DOAJ998f439604e74cef95464ecda676fa5a DE-627 ger DE-627 rakwb eng Haijiao Zhang verfasserin aut Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations. Science Q Samantha Savage verfasserin aut Anna Reister Schultz verfasserin aut Daniel Bottomly verfasserin aut Libbey White verfasserin aut Erik Segerdell verfasserin aut Beth Wilmot verfasserin aut Shannon K. McWeeney verfasserin aut Christopher A. Eide verfasserin aut Tamilla Nechiporuk verfasserin aut Amy Carlos verfasserin aut Rachel Henson verfasserin aut Chenwei Lin verfasserin aut Robert Searles verfasserin aut Hoang Ho verfasserin aut Yee Ling Lam verfasserin aut Richard Sweat verfasserin aut Courtney Follit verfasserin aut Vinay Jain verfasserin aut Evan Lind verfasserin aut Gautam Borthakur verfasserin aut Guillermo Garcia-Manero verfasserin aut Farhad Ravandi verfasserin aut Hagop M. Kantarjian verfasserin aut Jorge Cortes verfasserin aut Robert Collins verfasserin aut Daelynn R. Buelow verfasserin aut Sharyn D. Baker verfasserin aut Brian J. Druker verfasserin aut Jeffrey W. Tyner verfasserin aut In Nature Communications Nature Portfolio, 2016 10(2019), 1, Seite 13 (DE-627)626457688 (DE-600)2553671-0 20411723 nnns volume:10 year:2019 number:1 pages:13 https://doi.org/10.1038/s41467-018-08263-x kostenfrei https://doaj.org/article/998f439604e74cef95464ecda676fa5a kostenfrei https://doi.org/10.1038/s41467-018-08263-x kostenfrei https://doaj.org/toc/2041-1723 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2019 1 13
allfieldsGer	10.1038/s41467-018-08263-x doi (DE-627)DOAJ061547557 (DE-599)DOAJ998f439604e74cef95464ecda676fa5a DE-627 ger DE-627 rakwb eng Haijiao Zhang verfasserin aut Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations. Science Q Samantha Savage verfasserin aut Anna Reister Schultz verfasserin aut Daniel Bottomly verfasserin aut Libbey White verfasserin aut Erik Segerdell verfasserin aut Beth Wilmot verfasserin aut Shannon K. McWeeney verfasserin aut Christopher A. Eide verfasserin aut Tamilla Nechiporuk verfasserin aut Amy Carlos verfasserin aut Rachel Henson verfasserin aut Chenwei Lin verfasserin aut Robert Searles verfasserin aut Hoang Ho verfasserin aut Yee Ling Lam verfasserin aut Richard Sweat verfasserin aut Courtney Follit verfasserin aut Vinay Jain verfasserin aut Evan Lind verfasserin aut Gautam Borthakur verfasserin aut Guillermo Garcia-Manero verfasserin aut Farhad Ravandi verfasserin aut Hagop M. Kantarjian verfasserin aut Jorge Cortes verfasserin aut Robert Collins verfasserin aut Daelynn R. Buelow verfasserin aut Sharyn D. Baker verfasserin aut Brian J. Druker verfasserin aut Jeffrey W. Tyner verfasserin aut In Nature Communications Nature Portfolio, 2016 10(2019), 1, Seite 13 (DE-627)626457688 (DE-600)2553671-0 20411723 nnns volume:10 year:2019 number:1 pages:13 https://doi.org/10.1038/s41467-018-08263-x kostenfrei https://doaj.org/article/998f439604e74cef95464ecda676fa5a kostenfrei https://doi.org/10.1038/s41467-018-08263-x kostenfrei https://doaj.org/toc/2041-1723 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2019 1 13
allfieldsSound	10.1038/s41467-018-08263-x doi (DE-627)DOAJ061547557 (DE-599)DOAJ998f439604e74cef95464ecda676fa5a DE-627 ger DE-627 rakwb eng Haijiao Zhang verfasserin aut Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations. Science Q Samantha Savage verfasserin aut Anna Reister Schultz verfasserin aut Daniel Bottomly verfasserin aut Libbey White verfasserin aut Erik Segerdell verfasserin aut Beth Wilmot verfasserin aut Shannon K. McWeeney verfasserin aut Christopher A. Eide verfasserin aut Tamilla Nechiporuk verfasserin aut Amy Carlos verfasserin aut Rachel Henson verfasserin aut Chenwei Lin verfasserin aut Robert Searles verfasserin aut Hoang Ho verfasserin aut Yee Ling Lam verfasserin aut Richard Sweat verfasserin aut Courtney Follit verfasserin aut Vinay Jain verfasserin aut Evan Lind verfasserin aut Gautam Borthakur verfasserin aut Guillermo Garcia-Manero verfasserin aut Farhad Ravandi verfasserin aut Hagop M. Kantarjian verfasserin aut Jorge Cortes verfasserin aut Robert Collins verfasserin aut Daelynn R. Buelow verfasserin aut Sharyn D. Baker verfasserin aut Brian J. Druker verfasserin aut Jeffrey W. Tyner verfasserin aut In Nature Communications Nature Portfolio, 2016 10(2019), 1, Seite 13 (DE-627)626457688 (DE-600)2553671-0 20411723 nnns volume:10 year:2019 number:1 pages:13 https://doi.org/10.1038/s41467-018-08263-x kostenfrei https://doaj.org/article/998f439604e74cef95464ecda676fa5a kostenfrei https://doi.org/10.1038/s41467-018-08263-x kostenfrei https://doaj.org/toc/2041-1723 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 10 2019 1 13
language	English
source	In Nature Communications 10(2019), 1, Seite 13 volume:10 year:2019 number:1 pages:13
sourceStr	In Nature Communications 10(2019), 1, Seite 13 volume:10 year:2019 number:1 pages:13
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Science Q
isfreeaccess_bool	true
container_title	Nature Communications
authorswithroles_txt_mv	Haijiao Zhang @@aut@@ Samantha Savage @@aut@@ Anna Reister Schultz @@aut@@ Daniel Bottomly @@aut@@ Libbey White @@aut@@ Erik Segerdell @@aut@@ Beth Wilmot @@aut@@ Shannon K. McWeeney @@aut@@ Christopher A. Eide @@aut@@ Tamilla Nechiporuk @@aut@@ Amy Carlos @@aut@@ Rachel Henson @@aut@@ Chenwei Lin @@aut@@ Robert Searles @@aut@@ Hoang Ho @@aut@@ Yee Ling Lam @@aut@@ Richard Sweat @@aut@@ Courtney Follit @@aut@@ Vinay Jain @@aut@@ Evan Lind @@aut@@ Gautam Borthakur @@aut@@ Guillermo Garcia-Manero @@aut@@ Farhad Ravandi @@aut@@ Hagop M. Kantarjian @@aut@@ Jorge Cortes @@aut@@ Robert Collins @@aut@@ Daelynn R. Buelow @@aut@@ Sharyn D. Baker @@aut@@ Brian J. Druker @@aut@@ Jeffrey W. Tyner @@aut@@
publishDateDaySort_date	2019-01-01T00:00:00Z
hierarchy_top_id	626457688
id	DOAJ061547557
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ061547557</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309012537.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1038/s41467-018-08263-x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ061547557</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ998f439604e74cef95464ecda676fa5a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Haijiao Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Science</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Q</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Samantha Savage</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Reister Schultz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel Bottomly</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Libbey White</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Erik Segerdell</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beth Wilmot</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shannon K. McWeeney</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christopher A. Eide</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tamilla Nechiporuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amy Carlos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rachel Henson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chenwei Lin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Robert Searles</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hoang Ho</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yee Ling Lam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Richard Sweat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Courtney Follit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vinay Jain</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Evan Lind</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gautam Borthakur</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guillermo Garcia-Manero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Farhad Ravandi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hagop M. Kantarjian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jorge Cortes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Robert Collins</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daelynn R. Buelow</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sharyn D. Baker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Brian J. Druker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jeffrey W. Tyner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Nature Communications</subfield><subfield code="d">Nature Portfolio, 2016</subfield><subfield code="g">10(2019), 1, Seite 13</subfield><subfield code="w">(DE-627)626457688</subfield><subfield code="w">(DE-600)2553671-0</subfield><subfield code="x">20411723</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1038/s41467-018-08263-x</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/998f439604e74cef95464ecda676fa5a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1038/s41467-018-08263-x</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2041-1723</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_211</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="h">13</subfield></datafield></record></collection>
author	Haijiao Zhang
spellingShingle	Haijiao Zhang misc Science misc Q Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
authorStr	Haijiao Zhang
ppnlink_with_tag_str_mv	@@773@@(DE-627)626457688
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	20411723
topic_title	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
topic	misc Science misc Q
topic_unstemmed	misc Science misc Q
topic_browse	misc Science misc Q
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Nature Communications
hierarchy_parent_id	626457688
hierarchy_top_title	Nature Communications
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)626457688 (DE-600)2553671-0
title	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
ctrlnum	(DE-627)DOAJ061547557 (DE-599)DOAJ998f439604e74cef95464ecda676fa5a
title_full	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
author_sort	Haijiao Zhang
journal	Nature Communications
journalStr	Nature Communications
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2019
contenttype_str_mv	txt
container_start_page	13
author_browse	Haijiao Zhang Samantha Savage Anna Reister Schultz Daniel Bottomly Libbey White Erik Segerdell Beth Wilmot Shannon K. McWeeney Christopher A. Eide Tamilla Nechiporuk Amy Carlos Rachel Henson Chenwei Lin Robert Searles Hoang Ho Yee Ling Lam Richard Sweat Courtney Follit Vinay Jain Evan Lind Gautam Borthakur Guillermo Garcia-Manero Farhad Ravandi Hagop M. Kantarjian Jorge Cortes Robert Collins Daelynn R. Buelow Sharyn D. Baker Brian J. Druker Jeffrey W. Tyner
container_volume	10
format_se	Elektronische Aufsätze
author-letter	Haijiao Zhang
doi_str_mv	10.1038/s41467-018-08263-x
author2-role	verfasserin
title_sort	clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
title_auth	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
abstract	FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations.
abstractGer	FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations.
abstract_unstemmed	FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_211 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_2110 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4335 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
url	https://doi.org/10.1038/s41467-018-08263-x https://doaj.org/article/998f439604e74cef95464ecda676fa5a https://doaj.org/toc/2041-1723
remote_bool	true
author2	Samantha Savage Anna Reister Schultz Daniel Bottomly Libbey White Erik Segerdell Beth Wilmot Shannon K. McWeeney Christopher A. Eide Tamilla Nechiporuk Amy Carlos Rachel Henson Chenwei Lin Robert Searles Hoang Ho Yee Ling Lam Richard Sweat Courtney Follit Vinay Jain Evan Lind Gautam Borthakur Guillermo Garcia-Manero Farhad Ravandi Hagop M. Kantarjian Jorge Cortes Robert Collins Daelynn R. Buelow Sharyn D. Baker Brian J. Druker Jeffrey W. Tyner
author2Str	Samantha Savage Anna Reister Schultz Daniel Bottomly Libbey White Erik Segerdell Beth Wilmot Shannon K. McWeeney Christopher A. Eide Tamilla Nechiporuk Amy Carlos Rachel Henson Chenwei Lin Robert Searles Hoang Ho Yee Ling Lam Richard Sweat Courtney Follit Vinay Jain Evan Lind Gautam Borthakur Guillermo Garcia-Manero Farhad Ravandi Hagop M. Kantarjian Jorge Cortes Robert Collins Daelynn R. Buelow Sharyn D. Baker Brian J. Druker Jeffrey W. Tyner
ppnlink	626457688
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1038/s41467-018-08263-x
up_date	2024-07-03T21:20:22.011Z
_version_	1803594363849146368
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ061547557</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309012537.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1038/s41467-018-08263-x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ061547557</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ998f439604e74cef95464ecda676fa5a</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Haijiao Zhang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">FLT3 is commonly mutated in acute myeloid leukaemia and treatment with FLT3 inhibitors often ends with relapse. Here, the authors perform exome sequencing of samples from patients treated with the FLT3 inhibitor, crenolanib, to show that resistance occurs due to diverse molecular mechanisms, not primarily due to secondary FLT3 mutations.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Science</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Q</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Samantha Savage</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Reister Schultz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daniel Bottomly</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Libbey White</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Erik Segerdell</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beth Wilmot</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shannon K. McWeeney</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christopher A. Eide</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Tamilla Nechiporuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Amy Carlos</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rachel Henson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chenwei Lin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Robert Searles</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hoang Ho</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yee Ling Lam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Richard Sweat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Courtney Follit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vinay Jain</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Evan Lind</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gautam Borthakur</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guillermo Garcia-Manero</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Farhad Ravandi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hagop M. Kantarjian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jorge Cortes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Robert Collins</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Daelynn R. Buelow</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sharyn D. Baker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Brian J. Druker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jeffrey W. Tyner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Nature Communications</subfield><subfield code="d">Nature Portfolio, 2016</subfield><subfield code="g">10(2019), 1, Seite 13</subfield><subfield code="w">(DE-627)626457688</subfield><subfield code="w">(DE-600)2553671-0</subfield><subfield code="x">20411723</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:13</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1038/s41467-018-08263-x</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/998f439604e74cef95464ecda676fa5a</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1038/s41467-018-08263-x</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2041-1723</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_211</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2019</subfield><subfield code="e">1</subfield><subfield code="h">13</subfield></datafield></record></collection>
score	7.399083

Nicht das Richtige dabei?

Schreiben Sie uns!

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?